l E,GluudLL,KimerN,KragA.Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.AlimentaryPharmacology & Therapeutics,2012,36(7):619-626 ?2、ShahidHabib and Thomas D. Boyer.VasopressinV2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.TherapAdvGastroenterol, 2012,5(3):189-97?3、Long Yan,fengXie,etal.Thetreatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015; 15: 65 IF 5.727数据来源:Medline, Embase,Web of science等时间跨度:从数据库成立至2012.8关键词:Vaptans等观察:mortality 肝硬化并发症ascites correction of hyponatraemiaVaptans组与对照组相比,可明显升高血钠和降低体重,但在病死率、静脉曲张破裂出血、肝性脑病、自发性腹膜炎、肝肾综合征、肾衰竭等方面无明显差异。增加尿量过度增加引起的不良事件发生率。结果
全文预览
